This was the stock's third consecutive day of losses.

Accent Therapeutics appoints Serena Silver as chief scientific officer as it advances Phase I/II ATX-559 trials for advanced ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual ...

Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Analyst Evan Seigerman of BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

The stock's fall snapped a two-day winning streak.

Bristol Myers Squibb (NYSE: BMY) announced results from 18 presentations reinforcing its leadership in cell therapy, with data demonstrating efficacy, durability and safety of currently available ...

Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $59.38 which represents a slight increase of $0.54 or 0.92% from the prior close of $58.84. The stock opened at $58.84 and ...

Bristol-Myers Squibb Company (BMY), headquartered in New York and with a market cap of $121.6 billion, is a global leader in biopharmaceutical innovation. Known for its expertise in developing ...